Mark Shaefer
Biographic Data
| ID | 7560699 |
|---|---|
| NAME | Mark Shaefer |
| GIVEN NAMES | Mark |
| FAMILY NAME | Shaefer |
| SIGNATURE | SHAEFER M |
| AFFILIATIONS | ViiV Healthcare, Raleigh-Durham, Research Triangle Park, NC, USA |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
I feel empowered”: Women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain
Long-acting injectable antiretroviral therapy has been shown to be non-inferior to daily oral antiretroviral therapy in clinical trials and may soon become part of clinical care. While most trial participants to date have been men, approximately one quarter of ongoing Phase 3 trial participants are women offering an important opportunity to understand how long-acting antiretroviral therapy is perceived and experienced by women. We conducted in-de…
Patient-Reported Outcomes in Atlas and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled ana…
No prominent works on this page.
Patient-Reported Outcomes in Atlas and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled ana…
I feel empowered”: Women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain
Long-acting injectable antiretroviral therapy has been shown to be non-inferior to daily oral antiretroviral therapy in clinical trials and may soon become part of clinical care. While most trial participants to date have been men, approximately one quarter of ongoing Phase 3 trial participants are women offering an important opportunity to understand how long-acting antiretroviral therapy is perceived and experienced by women. We conducted in-de…
Antiretroviral therapy (2 works) · Family medicine (2 works) · HIV/AIDS Research and Interventions (2 works) · Human immunodeficiency virus (HIV (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Viral load (2 works) · Adolescent Sexual and Reproductive Health (1 works) · Adverse effect (1 works) · Alternative medicine (1 works)